Strides Pharma Ltd — Kya Buy Karna Chahiye? (Hinglish)
 |
Strides Pharma Ltd 2025 |
Summary/Quick Take: Strides Pharma aaj ₹934.70 (sample) par trade kar raha hai — 52-week high ₹978.40 aur low ₹513.05. Company ka P/E ~22.16, EPS ₹38.35, Debt/Equity 0.74. Is article mein hum fundamentals, technical levels, SWOT aur investment view short & long term mein dekhenge.
Company Overview
Strides Pharma (pharmaceutical manufacturing & formulations) global presence rakhta hai, generics aur niche dosage forms par focus. India + exports ke combination ki wajah se revenue diversification achhi hai, lekin regulatory risk aur competition bhi hai.
Key Numbers (Fundamentals)
| Market Cap | ₹7,834 Cr |
| P/E (TTM) | 22.16 |
| EPS (TTM) | ₹38.35 |
| P/B | 3.07 |
| ROE | 13.75% |
| Debt/Equity | 0.74 |
| Dividend Yield | 0.47% |
| Book Value | ₹276.85 |
Recent Price & Volume
- Today’s Low / High: ₹830.30 / ₹978.40
- Open / Prev. Close: ₹849.95 / ₹852.40
- Volume: 92,20,861 (high liquidity day)
- Lower circuit / Upper circuit: ₹681.95 / ₹1,022.85
Technical Levels (short-term)
- Support: ₹830 — ₹850 (intraday / short-term)
- Strong support zone: ₹700 — ₹750 (recent accumulation area)
- Resistance: ₹978 (52-week high). Break above ₹1,000 could trigger momentum buying.
- Volume spike indicates institutional interest — monitor closing above resistance with volume confirmation.
SWOT (Short)
- Strengths: Diversified product mix, export markets, reasonable ROE.
- Weaknesses: P/B ~3 and moderate debt — valuation not extremely cheap.
- Opportunities: Global generics demand, new product approvals, margin improvement.
- Threats: Regulatory inspections, pricing pressure, currency fluctuations.
Investment View
Short-term traders: Trade based on momentum — use support/resistance and strict stop-loss. High intraday volatility — be careful.
Medium-to-long term investors: Fundamentals appear solid (positive EPS, growing market). P/E ~22 vs industry P/E ~35 suggests relatively cheaper compared to industry — but validate growth outlook, margin trends and any one-time events from recent quarterly reports before buying. If you believe in company’s growth and regulatory track record, a phased buy (SIP/averaging) around support levels is prudent.
Risk Management
- Set stop-loss below nearest support (e.g., intraday SL ~ ₹810–820).
- Don’t allocate more than a predefined % of portfolio — diversify.
- Re-check quarterly results, promoter activity, and any regulatory news.
Conclusion
Strides Pharma dikhne mein fundamentally decent company hai with reasonable valuation compared to industry. Long-term holding ke liye consider kar sakte hain agar aapko management, growth pipeline aur balance sheet comfortable lage. Short-term mein momentum + volume pe trade possible hai — risk high hai, plan pe stick karein.
Want to track this stock?
Add to watchlist, set price alert around ₹1,000 (resistance) and ₹800 (support). Always re-check latest quarterly filing before increasing exposure.
Author: Anshul Finance
Published:
टिप्पणियाँ
एक टिप्पणी भेजें